bullish
Newron Pharmaceuticals - Evenamide Phase III at 30mg twice daily dose
SUMMARY
Newron is developing evenamide as an add-on to existing anti-psychotic therapies to treat poorly managed and refractory schizophrenia. A potentially pivotal Phase II/III study is starting in Europe, Asia and Latin America. This could report by Q422. It uses an intended therapeutic dose of 30mg twice per day. We maintain our indicative value of CHF121m.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- Newron Pharmaceuticals - Evenamide Phase III at 30mg twice daily dose08 Sep 2021
x